722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I

Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients

Topical cyclosporine vs tacrolimus for ocular GVHD prophylaxis after outpatient allogeneic hematopoietic stem cell transplantation A Phase I–II trial

Hallmarks of allogeneic hematopoietic cell transplant success A study on immune signatures and predictive features of graft versus host disease free remission states from the SFGM TC registry and cryostem biobank

Predicting donor engraftment success in adults post haploidentical bone marrow transplant for sickle cell disease BMT CTN 1507

The dimorphism at the HLA B leader and molecular HLA compatibility impact on haplo HSCT Experience of a single center based on ptcy strategies

Clinically meaningful improvement of the modified lee symptom score in patients treated with belumosudil for steroid refractory chronic GVHD Evidence from Canadian real world outcomes

ABC Highly active and entirely calcineurin and m TOR inhibitor free gvhd prevention regimen

Belumosudil for chronic graft versus host disease in children under 12 A retrospective analysis of effectiveness and safety

Persistent microbiome dysbiosis following hematopoietic cell transplantation Gut GvHD as the most severe manifestation of microbial disruption

Day 7 mount sinai acute GVHD international consortium MAGIC algorithm probability predicts GVHD and non GVHD related non relapse mortality in a contemporary cohort of allogeneic transplant patients

Stage 0 lower gastrointestinal LGI acute graft versus host disease aGVHD is associated with high response to non systemic treatment low incidence of moderate to severe chronic graft versus host disease cGVHD and low non relapse mortality NRM

Pharmacodynamic analysis of AGAVE 201 indicates changes in CSF 1R–expressing cells and associated biomarkers potentially contributing to chronic graft versus host disease resolution

Disruption of intestinal homeostasis reflected by DAO and microbiota alterations in gvhd post HSCT

Longitudinal multiproteomic analysis reveals persistent underlying inflammation in acute graft versus host disease patients responding to corticosteroid treatment

Human intestinal acute graft versus host disease is governed by a subset of transition like tissue resident memory CD8 T cells

Impact of ruxolitinib on corticosteroid treatment patterns in 1147 patients with chronic graft versus host disease in real world practice in the United States A long term follow up analysis

Vorinostat for GVHD prophylaxis in children adolescents and young adults AYA shows low incidence of acute GVHD and relapse with encouraging overall survival after allogeneic hematopoietic cell transplantation HCT A multisite nonrandomized clinical trial

IL 17 as a targetable pathway to reverse early NK cell dysregulation in high risk MDS with late relapse

Clinical and disease characteristics of initial participants at time of enrollment in THRIVE a prospective observational cohort study of patients at risk for chronic graft‑versus‑host disease